An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL/SLL

Br J Haematol. 2026 Apr;208(4):1287-1295. doi: 10.1111/bjh.70383. Epub 2026 Feb 24.

Abstract

This study explores the application of artificial intelligence technology for the quantitative analysis of immunohistochemical markers to differentiate between mantle cell lymphoma and chronic lymphocytic leukaemia/small lymphocytic lymphoma. Utilizing an AI-based platform, the research analysed the expression of CD3, CD5, CD10, CD20, CD23, Cyclin D1, BCL-2, BCL-6 and Ki-67 in 91 samples from 84 patients. The findings demonstrate that, compared to manual interpretation, the AI system provides more objective, reproducible and accurate measurement results. Additionally, this study introduces a virtual dual immunohistochemical labelling technique for simultaneous antigen visualization. Although limited by its single-centre retrospective design, the research establishes a promising AI-assisted framework that enhances the accuracy, standardization and diagnostic efficiency in distinguishing between these two clinically distinct lymphomas.

Keywords: artificial intelligence; chronic lymphocytic leukaemia/small lymphocytic lymphoma; immunohistochemistry; mantle cell lymphoma.

MeSH terms

  • Aged
  • Artificial Intelligence*
  • Biomarkers, Tumor* / analysis
  • Diagnosis, Differential
  • Female
  • Humans
  • Immunohistochemistry* / methods
  • Intelligent Systems
  • Leukemia, Lymphocytic, Chronic, B-Cell* / diagnosis
  • Leukemia, Lymphocytic, Chronic, B-Cell* / metabolism
  • Leukemia, Lymphocytic, Chronic, B-Cell* / pathology
  • Lymphoma, Mantle-Cell* / diagnosis
  • Lymphoma, Mantle-Cell* / metabolism
  • Lymphoma, Mantle-Cell* / pathology
  • Male
  • Retrospective Studies

Substances

  • Biomarkers, Tumor